Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
STK32A CRISPR/Cas9 KO Plasmid (h): sc-408625
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- STK32A CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the STK32A genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: STK32A Antibody (5H10): sc-135571
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
STK32A CRISPR/Cas9 KO Plasmid (h) | sc-408625 | 20 µg | $397.00 |
Overview
STK32A encodes a serine/threonine protein kinase implicated in phosphorylation-dependent control of cell signaling, with putative roles in regulating cellular growth, differentiation, and cytoskeletal-associated processes. As a kinase family member, STK32A is positioned to influence kinase cascades that shape transcriptional programs and stress-responsive signaling outputs. Altered kinase activity or expression is frequently linked to dysregulated proliferation and context-specific pathway rewiring in cancer and other complex diseases, making STK32A relevant for mechanistic studies. Characterizing STK32A-dependent phosphorylation networks can clarify how signaling connectivity changes across cell states and disease models.
STK32A CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the STK32A gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the STK32A together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the STK32A open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish STK32A protein expression.
This CRISPR knockout system enables efficient generation of STK32A-deficient cell models for investigation of STK32A signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting STK32A exon(s) critical for STK32A function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple STK32A genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by STK32A CRISPR/Cas9 KO Plasmid (h) and STK32A CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the STK32A locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by STK32A HDR Plasmid (h) and STK32A HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by STK32A homology arms to support homology-directed repair at defined STK32A target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.